CN109311892A - 手性吡咯并嘧啶化合物的制备方法 - Google Patents

手性吡咯并嘧啶化合物的制备方法 Download PDF

Info

Publication number
CN109311892A
CN109311892A CN201780037151.6A CN201780037151A CN109311892A CN 109311892 A CN109311892 A CN 109311892A CN 201780037151 A CN201780037151 A CN 201780037151A CN 109311892 A CN109311892 A CN 109311892A
Authority
CN
China
Prior art keywords
compound
formula
protecting group
preparation
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780037151.6A
Other languages
English (en)
Other versions
CN109311892B (zh
Inventor
张喜全
张爱明
周舟
姚华东
解杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings Beijing Co ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Shouyao Holdings Beijing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Shouyao Holdings Beijing Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN202010744086.4A priority Critical patent/CN111875607B/zh
Publication of CN109311892A publication Critical patent/CN109311892A/zh
Application granted granted Critical
Publication of CN109311892B publication Critical patent/CN109311892B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

一种手性吡咯并嘧啶化合物的制备方法及相关中间体。该方法使式A化合物与式6化合物或其盐反应得到式7化合物或式14化合物以及由式7化合物或式14化合物制备得到式Ⅰ化合物，以及所用中间体、中间体的制备方法和中间体在制备式Ⅰ化合物中的用途。所述制备方法具有步骤简短、高立体选择性、原子利用率高、反应条件温和、后处理简便的特点，避免使用价格昂贵的不对称反应催化剂，适合工业化生产。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201780037151.6A 2016-06-16 2017-06-15 手性吡咯并嘧啶化合物的制备方法 Active CN109311892B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010744086.4A CN111875607B (zh) 2016-06-16 2017-06-15 手性吡咯并嘧啶化合物的制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016104321265 2016-06-16
CN201610432126.5A CN107513069A (zh) 2016-06-16 2016-06-16 手性吡咯并嘧啶化合物的制备方法
PCT/CN2017/088421 WO2017215627A1 (zh) 2016-06-16 2017-06-15 手性吡咯并嘧啶化合物的制备方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010744086.4A Division CN111875607B (zh) 2016-06-16 2017-06-15 手性吡咯并嘧啶化合物的制备方法

Publications (2)

Publication Number Publication Date
CN109311892A true CN109311892A (zh) 2019-02-05
CN109311892B CN109311892B (zh) 2020-09-04

Family

ID=60663390

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201610432126.5A Pending CN107513069A (zh) 2016-06-16 2016-06-16 手性吡咯并嘧啶化合物的制备方法
CN201780037151.6A Active CN109311892B (zh) 2016-06-16 2017-06-15 手性吡咯并嘧啶化合物的制备方法
CN202010744086.4A Active CN111875607B (zh) 2016-06-16 2017-06-15 手性吡咯并嘧啶化合物的制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610432126.5A Pending CN107513069A (zh) 2016-06-16 2016-06-16 手性吡咯并嘧啶化合物的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010744086.4A Active CN111875607B (zh) 2016-06-16 2017-06-15 手性吡咯并嘧啶化合物的制备方法

Country Status (6)

Country Link
US (1) US10766901B2 (zh)
EP (1) EP3473625B1 (zh)
JP (1) JP6998896B2 (zh)
CN (3) CN107513069A (zh)
ES (1) ES2877678T3 (zh)
WO (1) WO2017215627A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3904356A4 (en) 2018-12-24 2022-09-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. THERAPEUTIC USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND
CN114981272A (zh) * 2020-03-09 2022-08-30 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物的治疗噬血细胞综合征的用途
MX2023002037A (es) 2020-08-18 2023-06-12 Incyte Corp Proceso e intermediarios para preparar un inhibidor de las cinasas de janus (jak).
EP4200278A1 (en) 2020-08-18 2023-06-28 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
AU2022296552A1 (en) 2021-06-21 2024-01-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrrolopyrimidine compound and pharmaceutical composition thereof for treating chronic graft versus host disease
WO2024042448A1 (en) * 2022-08-22 2024-02-29 Granules India Limited An improved process for the preparation of ruxolitinib

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065909A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
CN101448826A (zh) * 2005-12-13 2009-06-03 因塞特公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡咯和吡咯并[2,3-b]嘧啶
WO2011028685A1 (en) * 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN105777754A (zh) * 2014-12-16 2016-07-20 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5616499A (en) * 1979-07-19 1981-02-17 Yamasa Shoyu Co Ltd 6-c-purine nucleoside derivative and its preparation
JPS5841897A (ja) * 1981-09-04 1983-03-11 Yamasa Shoyu Co Ltd ６−（４−ピラゾリル）プリンリボヌクレオシド誘導体およびその製造法
JOP20190230A1 (ar) * 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
CN103739607A (zh) * 2014-01-22 2014-04-23 无锡方圆环球显示技术股份有限公司 一种基于三并咔唑多臂结构红光材料及其制备方法与应用
US9796733B2 (en) * 2014-06-04 2017-10-24 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
CN105218548A (zh) 2014-06-09 2016-01-06 上海海和药物研究开发有限公司 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途
CN105315286B (zh) * 2014-07-30 2018-08-17 连云港润众制药有限公司 西格列汀的制备
CN107759600A (zh) 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065909A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
CN1305479A (zh) * 1998-06-19 2001-07-25 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
CN101448826A (zh) * 2005-12-13 2009-06-03 因塞特公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡咯和吡咯并[2,3-b]嘧啶
WO2011028685A1 (en) * 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN105777754A (zh) * 2014-12-16 2016-07-20 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M.H.ELNAGDI,E TAL.: "Reaction with Heterocyclic Amidines Ⅷ.Synthesis of some New Imidazop[1,2-b]pyrazole Derivatives", 《J.HETEROCYCLIC CHEM.》 *

Also Published As

Publication number Publication date
CN111875607A (zh) 2020-11-03
CN111875607B (zh) 2021-12-03
EP3473625A4 (en) 2020-02-19
CN107513069A (zh) 2017-12-26
US10766901B2 (en) 2020-09-08
JP6998896B2 (ja) 2022-02-04
EP3473625B1 (en) 2021-06-02
ES2877678T3 (es) 2021-11-17
CN109311892B (zh) 2020-09-04
US20190211021A1 (en) 2019-07-11
EP3473625A1 (en) 2019-04-24
WO2017215627A1 (zh) 2017-12-21
JP2019523772A (ja) 2019-08-29

Similar Documents

Publication Publication Date Title
CN109311892A (zh) 手性吡咯并嘧啶化合物的制备方法
TWI663171B (zh) 噻吩并嘧啶衍生物之製造方法
CN108699063A (zh) 一种芦可替尼的合成工艺
TW201036946A (en) N-acylanthranilic acid derivative or salt thereof
CN102786525B (zh) N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
CA2741839A1 (en) 1-oxa-8-azaspiro [4,5] decane-8-carboxamide compounds as faah inhibitors
JP6944682B2 (ja) ベンゾイミダゾール系化合物の製造方法
CN113336689B (zh) 3-(α-氟乙烯基/羰基)吲哚类化合物的合成方法及抗癌活性
KR101165996B1 (ko) 프탈라지논 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
CN102030701A (zh) 一类Fluoradene衍生物及其制备方法
KR20140101895A (ko) ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체
JP2020518661A5 (zh)
TW200403211A (en) Peptide deformylase inhibitors
TW201904973A (zh) 作為mek抑制劑的類香豆素環類化合物及其應用
JP2008505175A (ja) ピロロトリアジン化合物の製造法
CN115385911A (zh) 一种二吡咯并吡啶结构的化合物、制备方法和医药用途
JP6134654B2 (ja) 複素環化合物およびその用途
KR20190025987A (ko) 가용성 구아닐레이트 시클라제 자극제의 신규 제조 방법
JP7357621B2 (ja) 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体
EP2465845A1 (en) Method for producing optically active 1-amino-2-vinylcyclopropanecarboxylic acid ester
CN111285792B (zh) 2-取代吲哚化合物及其制备方法
KR101187015B1 (ko) 키랄 촉매를 이용한 테트라하이드로퀴놀린 화합물의 제조방법
KR20160079560A (ko) 피롤 유도체 및 이의 제조 방법
IL281283B2 (en) Improved method for the production of 3-[(1S)-1-imidazolo[1,2-A]pyridine-6-ylethyl]-5-(1-methylpyrazol-1-YL]triazolo[4,5-B]pyrazine and polymeric forms His
CN110894186B (zh) 匹莫范色林及其中间体的制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190530

Address after: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369

Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Applicant after: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

Applicant after: Capital Pharmaceutical Holdings (Beijing) Co., Ltd.

Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369

Applicant before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Applicant before: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

Applicant before: Beijing Centaurus Biopharma Technology Co., Ltd.

GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369

Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Patentee after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Patentee after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd.

Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369

Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Patentee before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Patentee before: Shouyao holding (Beijing) Co.,Ltd.